Head-to-head evidence
Monorova vs Rosuvastatin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase · full Atherosclerotic Cardiovascular Disease pipeline
Monorova · Gemigliflozin
Developed by Yuhan Corporation
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Rosuvastatin
Marketed by AstraZeneca
NCT04964544 · Phase 3 · completed
This was a large but open-label, single-arm, uncontrolled study, so there was no randomization, blinding, or comparator arm. Its primary outcomes were descriptive self-selection measures and LDL-C change rather than a controlled clinical outcome, and no formal between-group primary endpoint comparison could be assessed.
Next expected readout: October 2026 · NCT06603363 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Monorova's landscape · Rosuvastatin's landscape